Skip to main content
SpringerLink
Log in

Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Glaucoma is a leading cause of visual morbidity throughout the world and is an age-related condition, the prevalence of which rises significantly with increasing age. Glaucoma, a condition affecting the optic nerve, has a variety of subtypes with multiple aetiological factors, the most important of which are intraocular pressure (IOP) and increasing age. Treatment by lowering of IOP is the only current method, for which there is evidence, by which the rate of progressive visual deterioration can be slowed or halted. Although there are surgical and laser treatments that are efficacious in lowering IOP, the most common manner in which patients with glaucoma control their IOP is with administration of daily topical ocular hypotensive drugs (eye drops). The variety of topical drugs utilised in the management of glaucoma all have the potential to have adverse effects and/or interactions with concomitant medications, many of which may be used for other age-related conditions. Adherence with appropriate medicines has a major effect on the outcome of medical conditions and this aspect applies to the management of glaucoma. There are certain specific issues that relate to the administration of topical agents, with respect to both adverse effects and adherence. Although many suspect poor adherence in elderly patients with glaucoma, relative to younger patients, adequate evidence for this is lacking. Furthermore, the manner by which adherence issues could be improved remains inadequately understood and poorly addressed. The aims of this article were to review, from a clinical perspective, the medical therapies currently used for glaucoma and discuss adherence issues with respect to the population of patients with glaucoma, who tend to be relatively elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17:190–5.

    PubMed  Google Scholar 

  3. Wensor MD, McCarty CA, Stanislavsky YL, et al. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105:733–9.

    CAS  PubMed  Google Scholar 

  4. Mitchell P, Smith W, Attebo K. et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103:1661–1669.

  5. Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology. 1994;101:1851–5.

    CAS  PubMed  Google Scholar 

  6. Martinez GS, Campbell AJ, Reinken J, et al. Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol. 1982;94:181–9.

    CAS  PubMed  Google Scholar 

  7. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369–74.

    CAS  PubMed  Google Scholar 

  8. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499–504.

    CAS  PubMed  Google Scholar 

  9. Quigley HA, Enger C, Katz J, et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol. 1994;112:644–9.

    CAS  PubMed  Google Scholar 

  10. Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol. 1995;113:918–24.

    CAS  PubMed  Google Scholar 

  11. Mukesh BN, McCarty CA, Rait JL, et al. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology. 2002;109:1047–51.

    PubMed  Google Scholar 

  12. Friedman DS, Jampel HD, Munoz B, et al. The prevalence of open-angle glaucoma among Blacks and Whites 73 years and older: The Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 2006;124:1625–30.

    PubMed  Google Scholar 

  13. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85–93.

    PubMed  Google Scholar 

  14. Zheng Y, Lavanya R, Wu R, et al. Prevalence and causes of visual impairment and blindness in an urban Indian population: the Singapore Indian Eye Study. Ophthalmology. 2011;118:1798–804.

    PubMed  Google Scholar 

  15. Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: The Los Angeles Latino Eye Study. Ophthalmology. 2012;119:2245–53.

    PubMed  PubMed Central  Google Scholar 

  16. David R, Tessler Z, Yassur Y. Epidemiology of acute angle-closure glaucoma: incidence and seasonal variations. Ophthalmologica. 1985;191:4–7.

    CAS  PubMed  Google Scholar 

  17. Teikari J, Raivio I, Nurminen M. Incidence of acute glaucoma in Finland from 1973 to 1982. Graefes Arch Clin Exp Ophthalmol. 1987;225:357–60.

    CAS  PubMed  Google Scholar 

  18. Fujita K, Negishi K, Fujiki K, et al. Epidemiology of acute angle-closure glaucoma. Jpn J Clin Ophthalmol. 1996;37:625–9.

    Google Scholar 

  19. Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in Singapore. An island-wide survey. Arch Ophthalmol. 1997;115:1436–40.

    CAS  PubMed  Google Scholar 

  20. Wong TY, Foster PJ, Seah SK, et al. Rates of hospital admissions for primary angle closure glaucoma among Chinese, Malays, and Indians in Singapore. Br J Ophthalmol. 2000;84:990–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Lai JS, Liu DT, Tham CC, et al. Epidemiology of acute primary angle-closure glaucoma in the Hong Kong Chinese population: prospective study. Hong Kong Med J. 2001;7:118–23.

    CAS  PubMed  Google Scholar 

  22. Ivanisević M, Erceg M, Smoljanović A, et al. The incidence and seasonal variations of acute primary angle-closure glaucoma. Coll Antropol. 2002;26:41–5.

    PubMed  Google Scholar 

  23. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.

    PubMed  Google Scholar 

  24. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.

    PubMed  Google Scholar 

  25. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56.

    PubMed  Google Scholar 

  26. The Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.

    Google Scholar 

  27. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology. 2001;108:247–53.

    CAS  PubMed  Google Scholar 

  28. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001;131:699–708.

    CAS  PubMed  Google Scholar 

  29. Hafez AS, Lesk MR. Role of ocular blood flow in the pathogenesis of glaucoma. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 88–97.

    Google Scholar 

  30. Tanna AP. Normal-tension glaucoma. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 378–86.

    Google Scholar 

  31. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–53.

    CAS  PubMed  Google Scholar 

  32. The Advanced Glaucoma Intervention Study. (AGIS) Investigators. The Advanced Glaucoma Intervention Study (AGIS 7): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.

    Google Scholar 

  33. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study (AGIS). Ophthalmology. 2004;111:1627–35.

    PubMed  Google Scholar 

  34. Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030–6.

    PubMed  Google Scholar 

  35. Chauhan BC, Mikelberg FS, Artes PH, et al. Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. Arch Ophthalmol. 2010;128:1249–55.

    PubMed  Google Scholar 

  36. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost treatment for open angle glaucoma. The United Kingdom Glaucoma Treatment Study: a multicentre, randomised, placebo-controlled clinical trial. Lancet. 2014. doi:10.1016/S0140-6736(14)62111-5.

    PubMed  Google Scholar 

  37. Friedman DS, Freeman E, Munoz B, et al. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. Ophthalmology. 2007;114:2232–7.

    PubMed  Google Scholar 

  38. Haymes SA, LeBlanc RP, Nicholela MT, et al. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149–55.

    PubMed  Google Scholar 

  39. Lee AJ, Wang JJ, Kifley A, et al. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113:1069–76.

    PubMed  Google Scholar 

  40. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol. 2004;242:397–401.

    PubMed  Google Scholar 

  41. Knudtson MD, Klein BE, Klein R, et al. Age-related eye disease, quality of life, and functional activity. Arch Ophthalmol. 2005;123:807–14.

    PubMed  Google Scholar 

  42. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology. 2003;110:1292–6.

    PubMed  Google Scholar 

  43. Zimmerman TJ, Kaufman HE, Timolo S. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601–4.

    CAS  PubMed  Google Scholar 

  44. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol. 1978;96:2045–8.

    CAS  PubMed  Google Scholar 

  45. Urtti A, Rouhiainen H, Kaila T, Saana V. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm Res. 1994;11:1278–82.

    CAS  PubMed  Google Scholar 

  46. Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol. 1986;102:606–11.

    CAS  PubMed  Google Scholar 

  47. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed ß-blockers. JAMA. 1986;255:357–60.

    CAS  PubMed  Google Scholar 

  48. Kaeser HE. Drug-induced myasthenic syndromes. Acta Neurologica Scandinavica. 1984;100:39–47.

    CAS  PubMed  Google Scholar 

  49. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36:504–11.

    CAS  PubMed  Google Scholar 

  50. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53:S107–20.

    PubMed  PubMed Central  Google Scholar 

  51. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41:S105–10.

    PubMed  Google Scholar 

  52. Hedner J, Everts B, Möller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol. 1999;117:1305–9.

    CAS  PubMed  Google Scholar 

  53. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47:S6–12.

    PubMed  Google Scholar 

  54. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11:94–100.

    CAS  PubMed  Google Scholar 

  55. Krauss AHP, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004;49:S5–11.

    PubMed  Google Scholar 

  56. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19:87–112.

    CAS  PubMed  Google Scholar 

  57. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox. Am J Ophthalmol. 1954;37:13–5.

    CAS  PubMed  Google Scholar 

  58. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44:S119–29.

    PubMed  Google Scholar 

  59. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects: serum chemical analysis. Arch Ophthalmol. 1977;95:1378–82.

    CAS  PubMed  Google Scholar 

  60. Silver LH. The Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400–8.

    CAS  PubMed  Google Scholar 

  61. Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharm Ther. 1997;13:23–30.

    CAS  Google Scholar 

  62. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humour dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–7.

    CAS  PubMed  Google Scholar 

  63. Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2 %). J Fr Ophtalmol. 2000;23:763–8.

    CAS  PubMed  Google Scholar 

  64. Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456–61.

    CAS  PubMed  Google Scholar 

  65. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586–91.

    CAS  PubMed  Google Scholar 

  66. Reynolds AC. Alpha agonists. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 566–76.

    Google Scholar 

  67. Gerente VM, Biondi AC, Barbosa CP, et al. Effect of brimonidine tartrate 0.15 % on scotopic pupil: controlled trial. J Ocul Pharm Ther. 2007;23:476–480.

  68. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119–26.

    PubMed  Google Scholar 

  69. Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37:21–6.

    PubMed  Google Scholar 

  70. Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998;12:225–41.

    CAS  PubMed  Google Scholar 

  71. Acheampong A, Tang-Liu DDS. Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay. J Pharm Biomed Anal. 1995;13:995–1002.

    CAS  PubMed  Google Scholar 

  72. Drance SM, Bensted M, Schulzer M. Pilocarpine and intraocular pressure. Duration of effectiveness of 4 percent and 8 percent pilocarpine instillation. Arch Ophthalmol. 1974;91:104–6.

    CAS  PubMed  Google Scholar 

  73. Grierson I, Lee WR, Abraham S. Effects of pilocarpine on the morphology of the human outflow apparatus. Br J Ophthalmol. 1978;62:302–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Shiroma LO, Costa VP. Parasympathomimetics. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma: medical diagnosis and therapy. London: Elsevier Saunders; 2015. p. 577–82.

    Google Scholar 

  75. D’Alena P, Ferguson W. Adverse effects after glycerol orally and mannitol parenterally. Arch Ophthalmol. 1966;75:201–3.

    PubMed  Google Scholar 

  76. Frank MSB, Nahata MC, Hilty MD. Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use. Pharmacotherapy. 1981;1:147–60.

    CAS  PubMed  Google Scholar 

  77. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.

    PubMed  PubMed Central  Google Scholar 

  78. Hopes M, Broadway DC. Preservative-free treatment in glaucoma is a sensible and realistic aim for the future. Eur Ophthalmol Rev. 2010;4:23–8.

    Google Scholar 

  79. Stewart WC, Day DG, Holmes KT, et al. Effect of timolol 0.5 % gel and solution on pulmonary function in older glaucoma patients. J Glaucoma. 2001;10:227–32.

    CAS  PubMed  Google Scholar 

  80. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134:749–60.

    CAS  PubMed  Google Scholar 

  81. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 1993;116:600–11.

    CAS  PubMed  Google Scholar 

  82. Quaranta L, Katsanos A, Floriani I, et al. Circadian intraocular pressure and blood pressure reduction with Timolol 0.5 % solution and Timogel 0.1 % in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52:1552–7.

    CAS  PubMed  Google Scholar 

  83. Broadway DC, Drance SM. Glaucoma and vasospasm. Br J Ophthalmol. 1998;82:862–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Meuche C, Heidrich H, Bleckmann H. Raynaud syndrome following timolol-containing eyedrops. Fortschr Ophthalmol. 1990;87:45–7.

    CAS  PubMed  Google Scholar 

  85. Franssen C, Wollersheim H, de Haan A, et al. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud’s phenomenon and in hypertension. J Clin Pharmacol. 1992;32:652–9.

    CAS  PubMed  Google Scholar 

  86. Khawaja AP, Chan MP, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014;121:1501–7.

    PubMed  PubMed Central  Google Scholar 

  87. Spooner JJ, Bullano M, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 2002;8:S255–61.

    Google Scholar 

  88. Cate H, Bhattacharya D, Clark A, et al. Improving adherence to glaucoma medication: a randomized controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). BMC Ophthalmol. 2014;14:32.

    PubMed  PubMed Central  Google Scholar 

  89. Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Surv Ophthalmol. 1990;35:205–18.

    CAS  PubMed  Google Scholar 

  90. Kinoshita H, Taniguchi T, Nishiguchi M, et al. An autopsy case of combined drug intoxication involving verapamil, metoprolol and digoxin. Forensic Sci Int. 2003;133:107–12.

    CAS  PubMed  Google Scholar 

  91. Thomson Healthcare Inc. Interaction effects of apraclonidine, brimonidine, and monoamine oxidase inhibitors. Micromedex 2007 and United States Pharmacopeia 2004.

  92. Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamine and cyclosporine. Arch Ophthalmol. 1998;116:832–3.

    CAS  PubMed  Google Scholar 

  93. Steinert RF, Thomas JV, Boger WP 3rd. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99:100–3.

    CAS  PubMed  Google Scholar 

  94. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32:3145–66.

    CAS  PubMed  Google Scholar 

  95. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83–91.

    CAS  PubMed  Google Scholar 

  96. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983;28:S252–8.

    Google Scholar 

  97. Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma. 1992;1:134–8.

    Google Scholar 

  98. Schwartz GF. Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma. Am J Ophthalmol. 2004;137:S1–2.

    PubMed  Google Scholar 

  99. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130:65S–72S.

    PubMed  Google Scholar 

  100. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.

  101. Schwartz GF, Platt R. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. Am J Manag Care. 2002;8:S278–80.

    PubMed  Google Scholar 

  102. Deokule S, Sadiq S, Shah S. Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms. Ophthalmic Physiol Opt. 2004;24:9–15.

    PubMed  Google Scholar 

  103. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers and glaucoma; a systematic classification. J Glaucoma. 2003;12:393–8.

    PubMed  Google Scholar 

  104. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116:191–9.

    PubMed  Google Scholar 

  105. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524–30.

    CAS  PubMed  Google Scholar 

  106. Kass MA, Gordon M, Morley RE Jr, et al. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103:188–93.

    CAS  PubMed  Google Scholar 

  107. Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–6.

    PubMed  Google Scholar 

  109. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–4.

    PubMed  Google Scholar 

  110. Stewart WC, Chorak RP, Hunt HH, et al. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176–81.

    CAS  PubMed  Google Scholar 

  111. Caprioli J, Coleman AL. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology. 2008;115:1123–9.

    PubMed  Google Scholar 

  112. Rossi GC, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21:410–4.

    PubMed  Google Scholar 

  113. Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118:2398–402.

    PubMed  PubMed Central  Google Scholar 

  114. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606.

    PubMed  Google Scholar 

  115. Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 1995;26:233–6.

    CAS  PubMed  Google Scholar 

  116. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005;112:953–61.

    PubMed  Google Scholar 

  117. Sackett D, Jackett D, Snow J. Magnitude and measurement of compliance. In: Haynes B, Wayne Taylor D, Sackett D (eds.) Compliance in healthcare. Baltimore, London: The John Hopkins University Press; 1979. pp. 11–22.

  118. Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye. 2009;23:924–32.

    CAS  PubMed  Google Scholar 

  119. Cooper C, Dennison E, Edwards M, Litwic A. Epidemiology of osteoarthritis. Medicographia. 2013;35:145–51.

    Google Scholar 

  120. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998;13:5–10.

    CAS  PubMed  Google Scholar 

  121. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer Dement. 2013;9(63–75):e2.

    Google Scholar 

  122. Kass MA, Hodapp E, Gordon M, et al. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol. 1982;14:775–9.

    CAS  PubMed  Google Scholar 

  123. Kass MA, Hodapp E, Gordon M, et al. Patient administration of eyedrops: observation. Part II. Ann Ophthalmol. 1982;14:889–93.

    CAS  PubMed  Google Scholar 

  124. Tsai T, Robin AL, Smith JP III. An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29–35.

    PubMed  PubMed Central  Google Scholar 

  125. Kahook MY. Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives. Expert Rev Med Devices. 2007;4:261–6.

    CAS  PubMed  Google Scholar 

  126. Sclar DA, Skaer TL, Chin A, et al. Effectiveness of the C CapTM in promoting prescription refill compliance among patients with glaucoma. Clin Ther. 1991;13(3):396–400.

    CAS  PubMed  Google Scholar 

  127. Hughes C. Medication non-adherence in the elderly. Drugs Aging. 2004;21:793–811.

    PubMed  Google Scholar 

  128. Cate H, Battacharya D, Clark A, et al. Patterns of adherence behaviour for patients with glaucoma. Eye. 2013;27:545–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Giaconi JA, Law SK, Coleman AL, Caprioli J (eds). Pearls of glaucoma management. 1st edition. Heidleberg: Springer; 2010. p. 235.

  130. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: Adherence by the elderly. Am J Pub Health. 1993;83:711–6.

    CAS  Google Scholar 

  131. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18:401–9.

    CAS  PubMed  Google Scholar 

  132. Chang DS, Friedman DS, Frazier T, et al. Development and validation of a predictive model for nonadherence with once-daily glaucoma medications. Ophthalmology. 2013;120:1396–402.

    PubMed  PubMed Central  Google Scholar 

  133. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30–6.

    PubMed  Google Scholar 

  134. Domino FJ. Improving adherence to treatment for hypertension. Am Fam Physician. 2005;71:2089–90.

    PubMed  Google Scholar 

  135. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997;95:1085–90.

    CAS  PubMed  Google Scholar 

  136. Sheppard J, Warner J, Kelley K. An evaluation of the effectiveness of a nurse-led glaucoma monitoring clinic. Ophthalmic Nurs. 2003;7:15–21.

    Google Scholar 

  137. Beckers HJ, Webers CA, Busch MJ, et al. Adherence improvement in Dutch glaucoma patients: a randomized controlled trial. Acta Ophthalmol. 2013;91:610–8.

    PubMed  Google Scholar 

  138. Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J. 1979;2:1031–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  139. Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009;116:2286–93.

    PubMed  PubMed Central  Google Scholar 

  140. Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010;19:66–72.

    PubMed  PubMed Central  Google Scholar 

  141. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540–50.

    PubMed  Google Scholar 

  142. Gray TA, Fenerty C, Harper R, et al. Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial. Eye. 2012;26:407–17.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

David C. Broadway and Heidi Cate have no acknowledgments in respect of this review.

Author contributions

Both authors devised the concept of the article and contributed equally to the research and writing of the manuscript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Norfolk and Norwich University Hospital, Colney Lane, Norwich, Norfolk, NR4 7UY, UK

    David C. Broadway & Heidi Cate

  2. School of Pharmacy, University of East Anglia, Norwich, UK

    David C. Broadway & Heidi Cate

  3. School of Biological Science, University of East Anglia, Norwich, UK

    David C. Broadway

Authors
  1. David C. Broadway
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heidi Cate
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Broadway.

Ethics declarations

Conflicts of interest

David C. Broadway and Heidi Cate have no conflicts of interest to declare that are of direct relevance to the content of this review. No sources of funding were used to assist in the preparation and/or writing of this review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Broadway, D.C., Cate, H. Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma. Drugs Aging 32, 569–581 (2015). https://doi.org/10.1007/s40266-015-0282-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0282-9

Keywords

Search

Navigation